See the latest Coronavirus Information including vaccinations, testing sites, visitation restrictions, and more.
English and French
English and French
Perelman Center for Advanced Medicine
Abramson Cancer Center, West Pavilion, 3rd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Cadoo K, Simpkins F, Mathews C, Kabil N, Bennett J, Aghajanian C.: Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study. ASCO (Virtual) : 2020.
Kim H, Xu, H, George E, Hallberg D, Kumar s, Jagannathan V, Medvedev S, Kinose Y, Devins K, Verma P, Ly K, Wang Y, Greenbure RA, Schwartz L, Johnson N, Scharpf R, Mills G, Zhang R, Velculesco V, Brown E, Simpkins F.: Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. June, 2020 in press. Nature Communications : 2020.
Lin LL, Lakomy DS, Ning MS, Simpkins F, Jhingran A.: Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin. Int J Gynecol Cancer. : 30(4):409-423,2020.
Rodriguez-Garcia A, Sharma P, Poussin M, Boesteanu AC, Minutolo NG, Gitto SB, Omran DK, Robinson MK, Adams GP, Simpkins F, Powell DJ Jr.: CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
Mol Ther. : 28(2):548-560,2020.
Nasioudis D, Latif NA, Simpkins F, Cory L, Giuntoli RL 2nd, Haggerty AF, Morgan MA, Ko EM.: Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base.
Gynecol Oncol. : 156(2):315-319,2020.
Gitto SB, Kim H, Rafail S, Omran DK, Medvedev S, Kinose Y, Rodriguez-Garcia A, Flowers AJ, Xu H, Schwartz LE, Powell DJ Jr, Simpkins F.: An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
Gynecol Oncol. : 156(1):222-232,2020.
Kinose Y, Kim H, Xu H, Medvedev S, George E, Gitto S, Whicker M, Hallberg D, Schwartz L, Mills G, Velculescu VE, Wang T, Drapkin R, Simpkins F.: Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear-cell ovarian cancers AACR Advances in Ovarian Cancer Research Meeting, Atlanta, GA, Sept, 2019. AACR Advances in Ovarian Cancer Research Meeting, Atlanta, GA, : 2019.
Hyoung Kim, Veena Jagnnathan, Dorothy Halberg, Haineng Xu, Erin George, Sergey Medvedev, Yasuto Kinose, Anne van Harten, Victor Velculesco, Eric Brown, Fiona Simpkins: Optimizing DDRi combinations by genetic context in ovarian cancers from germline BRCA carriers. Basser Symposium for BRCA : 2019.
Arlene Garcia, Natalie MacKenzie, Margaret Whicker, Joseph Lucci, Matt Pearson, Loraine Portelance, Gordon Mills, Lilie Lin, Fiona Simpkins: Phase I clinical trial of nelfinavir and chemoradiation in locally advanced cervix cancer. SGO, Honolulu, HI : 2019.
*Simpkins F, Jang K, Yoon H, Hew K, Kim M, Azzam D, Sun J, Zhao D, Ince, T, Liu W, Guo W, Zhi Wei, Zhang G, Mills G, *Slingerland JM: *Co-corresponding authors. Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells. Clin Cancer Res : 2018.
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine3400 Civic Center Blvd., 3rd Floor West
Patient appointments: 800-789-7366
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.